Sign in
Taking people in United StatesPhase 2

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

Key facts

Who runs it
NYU Langone Health
Where
New York, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
26 May 2021
Planned end
Jun 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cannabidiol
  • Placebo
Record updated
17 February 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Meets clinical criteria for Posttraumatic Stress Disorder (PTSD) as per Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  • TBI present (for PTSD+TBI subjects only) as per American Congress of Rehabilitation Medicine (ACRM) definition
  • Mild TBI (for PTSD+TBI subjects only) as per Ohio State University Identification Screener
  • Able to provide at least 2 locators
  • Able to provide informed consent
  • Confirmation that the participant is reliably domiciled
  • Agreement to abstain from all other cannabinoid use for the duration of the study
  • Willingness to use contraception if of childbearing potential

Who cannot take part

  • Positive urine drug screen (Positive for cannabinoids, amphetamine, cocaine, opioids)
  • Currently prescribed medications with possible CBD-drug interactions
  • History of open head injury
  • Lifetime history of any psychiatric disorder with psychotic features, bipolar disorder
  • Psychotherapy for PTSD or other psychiatric conditions initiated within 2 months of screening
  • Not stable for at least 2 months on psychiatric medication, anticonvulsants, antihypertensive medication, sympathomimetic medication, estrogen replacement therapy, medications associated with neurogenesis, or steroid medication
  • Current significant suicidality (assessed using the C-SSRS), any significant suicidal behavior in the past 12 months, or any history of serious suicide attempts requiring hospitalization, or current significant homicidality
  • Neurologic disorder or systemic illness affecting CNS function (apart from TBI)
  • Major medical illness (i.e. cancer or infectious disease.)
  • Significant allergic reactions to the drug including cannabinoids or sesame oil
  • Has a high risk of adverse emotional or behavioral reaction (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, and lack of meaningful social support)
  • Inpatient psychiatric treatment in past 12 months, with the exception of detox and extended ED stays
  • Significant laboratory abnormalities, significantly impaired hepatic function, abnormalities in complete blood count or metabolic panel
  • TBI within the last 6 months
  • Moderate or Severe TBI
  • SUD in the last 12 months other than mild AUD or nicotine use
  • Use of any cannabinoid containing product within the last 1 month
  • Exposure to trauma in the last 30 days, including police duty or military service
  • Active suicide attempt within the past year
  • Clinical diagnosis of anemia, advised by physician to avoid blood draws
  • Pregnancy or lactation
  • Contraindication to MRI
  • Males and females who plan to conceive a child during or two weeks following the study
  • Active legal problems likely to result in incarceration within 12 weeks of treatment initiation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • New York University School of MedicineNew York, United StatesContact: Esther M Blessing, MD PhDTaking people

About the trial

What the trial wants to find out

This will be a randomized placebo controlled study to test the efficacy of cannabidiol (CBD) as a treatment for symptoms of post-traumatic stress disorder (PTSD). Subjects, 120 in total, will be males and females with PTSD, half of which will have comorbid mild traumatic brain injury (TBI). There will be three study arms, each with 40 subjects: 1) Oral CBD 400 mg daily; 2) Oral CBD 800 mg daily, and 3) Placebo daily. Treatment duration will be 8 weeks. The primary outcome will be change in PTSD symptoms as measured by change in the Clinician-Administered PTSD Scale (CAPS-5) total score.

The 3 groups in the trial

  • Cannabidiol Group 1Existing treatment, for comparison

    40 participants will be titrated to a maximum dose of oral cannabidiol 800 mg daily over 2 weeks for a total of 8 weeks treatment.

    Treatment: Cannabidiol

  • Cannabidiol Group 2Existing treatment, for comparison

    40 participants will be titrated to a maximum dose of oral cannabidiol 400 mg daily over 2 weeks for a total of 8 weeks treatment.

    Treatment: Cannabidiol

  • Placebo GroupPlacebo, for comparison

    40 participants will be given a placebo for a total of 8 weeks treatment.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response.
Fit questions
Built from NCT04550377, who can take part
Record updated
17 February 2026